Delivery of the NRG1 antagonist directly into the central nervous system (CNS) is important in light of other findings suggesting that NRG1 may still be needed to maintain neuromuscular junctions and can be protective in ALS animal models [65–67]. This evidence concerns the gene NRG1 and amyotrophic lateral sclerosis.